GlassScriptPhysician profile
Jonathan S Treisman
NPI 1699778860
$42,959.64
in general payments reported to CMS, 2019-2025
20 companies · $427 in 2025
The $427 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $130 · 2021: $137 · 2022: $370 · 2023: $20K · 2024: $21K · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Travel and Lodging: $4,002 · Food and Beverage: $2,044 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,475.00 |
| Travel and Lodging | $4,002.05 |
| Food and Beverage | $2,043.99 |
| Education | $130.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $40,313.72 | 2023-2024 | Erleada, Akeega |
| Merck Sharp & Dohme LLC | $560.37 | 2019-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $377.94 | 2019-2023 | Enhertu |
| Kite Pharma, INC. | $321.78 | 2019-2024 | |
| Celgene Corporation | $288.60 | 2019-2025 | Opdivo |
| Amgen INC. | $152.49 | 2019-2024 | Imdelltra (Amg 757), Lumakras |
| Legend Biotech USA INC. | $128.08 | 2025 | Carvykti |
| Seagen INC. | $125.00 | 2023 | Adcetris |
| Astellas Pharma US INC | $125.00 | 2024 | Cresemba |
| Myriad Genetic Laboratories, INC. | $106.83 | 2022 | |
| Exelixis INC. | $99.99 | 2023 | |
| Genzyme Corporation | $97.33 | 2023 | |
| Janssen Scientific Affairs, LLC | $76.39 | 2024 | Darzalex, Imbruvica, Tecvayli |
| Adaptive Biotechnologies Corporation | $41.55 | 2023 | Clonoseq |
| Taiho Oncology, INC. | $38.95 | 2023-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $38.15 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $22.93 | 2019 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Janssen Pharmaceuticals, INC | $12.62 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Treisman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.